User profiles for Joanna I. López-Velazco

Joanna I. LópezVelazco

Biogipuzkoa (Previously Known As Biodonostia) Health Research Institute
Verified email at biodonostia.org
Cited by 37

[HTML][HTML] Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment

…, P Azcoaga, JI López-Velazco… - The Journal of …, 2022 - Am Soc Clin Investig
The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all
stages of tumor progression. The contribution of stromal cells to the reprogramming of the …

Acetyl-CoA carboxylase 1 controls a lipid droplet–peroxisome axis and is a vulnerability of endocrine-resistant ER+ breast cancer

…, R El Botty, M Benelli, JI López-Velazco… - Science Translational …, 2024 - science.org
Targeting aromatase deprives ER + breast cancers of estrogens and is an effective
therapeutic approach for these tumors. However, drug resistance is an unmet clinical need. …

[HTML][HTML] A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer

JI López-Velazco, S Manzano, M Otaño… - Breast Cancer …, 2024 - Springer
Background Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive (ER+) /HER2-negative
(HER2-) breast cancer allows real-time evaluation of drug efficacy as well as …

Stromal Oncostatin M axis promotes breast cancer progression

AM Araujo, A Abaurrea, P Azcoaga, JI López-Velazco… - bioRxiv, 2020 - biorxiv.org
Cancer cells are constantly communicating with the surrounding tumour microenvironment (TME)
and they hijack physiological cell interactions to overcome immune system …

Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis …

JIL Velazco, M Otaño, I Lacambra, K Elorriaga… - Cancer Research, 2022 - AACR
Background. Neoadjuvant endocrine therapy (NET) in luminal breast cancer (LBC) is the
perfect scenario for real-time evaluation of the biological and molecular changes that occur …

Abstract PS5-39: Tumour cellularity size as a biomarker to predict response after neoadjuvant endocrine therapy: Correlation analysis between Ki67 expression and …

JIL Velazco, M Otaño, L Larburu, A Lahuerta… - Cancer Research, 2021 - AACR
Background: Neoadjuvant endocrine therapy (NET) is an approach that allows real-time
evaluation of drug efficacy as well as investigation of the biological and molecular changes that …

Role of Oncostatin M signalling axis in breast cancer progression: Implications in the tumour microenvironment

AS Monteiro Araujo - 2021 - addi.ehu.es
I would like to thank my PhD supervisors Dr. Charles Lawrie and Dr. Maria Caffarel for giving
me the opportunity to develop this project and for all support and intellectual guidance …

[PDF][PDF] My book on The Positive and Negative Sides of Globalization. AKA the brilliant and dark sides of Globalization. 778 pages total

O Lazin - academia.edu
… Deseamos reconocer el trabajo editorial de Adriana Patricia López Velazco, cuyas
contribuciones trascienden con mucho la función de coordinadora de esta serie. Paty tiene una facul…

[PDF][PDF] Estereotipos de género en adolescentes mexicanas/os Gender stereotypes in mexican teenagers

JCC Ríos - FACULTAD DE CIENCIAS DE LA …, 2020 - biblioteca-repositorio.clacso.edu.ar
The following text presents a research report, whose purpose was to evaluate gender
stereotypes in educated teenagers from Puerto Vallarta, Mexico during 2018. Methodology: A …

[CITATION][C] Tumour cellularity size as a biomarker to predict response after neoadjuvant endocrine therapy: Correlation analysis between Ki67 expression and PEPI …

JI Lopez Velazco, M Otano… - CANCER …, 2021 - AMER ASSOC CANCER …